Characterization of intestinal regeneration in a model of intestinal atresia
Characterization of intestinal regeneration in a model of intestinal atresia
批准号:
8617840
负责人:
Peter F Nichol
金额:
$7.53万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-02-15 至 2015-01-31
关键词:
AddressApoptosisApoptoticAreaBehaviorCaloriesCell LineageCellsColonColorCongenital AbnormalityCost of IllnessCountryDataDefectDevelopmentDiseaseDistalEmbryoEndodermEndoderm CellEnterocytesEventFailureFamilyFutureGenesGeneticGerm LayersGoalsHealthHumanInjuryInterventionIntestinal AtresiaIntestinal NeoplasmsIntestinal ObstructionIntestinesInvadedInvestigationKnowledgeLaboratoriesLateralLearningLengthLifeMesodermMissionModelingMutationNatural regenerationNatureNewborn InfantNutrientNutritional RequirementsOrganismPatientsPhasePhenotypePopulationProcessResearchShort Bowel SyndromeStable PopulationsSurfaceSyndromeTestingTherapeuticTimeTissuesTubeUnited States National Institutes of HealthWorkburden of illnesscell typedesigndisabilityinnovationinsightkeratinocyte growth factor receptormeetingsmouse modelmutantnovelpostnatalpublic health relevancereconstitutionregenerativeregenerative therapyresearch studyresponsetransdifferentiation
中文摘要
描述(由申请人提供):在本提案中,我们使用先天性人类缺陷的遗传小鼠模型来研究胚胎肠内以前未知的再生机制。先天性缺陷是一种肠闭锁,它在产前形成,并导致部分肠管的节段性缺失。闭锁新生儿时期出现的一种肠梗阻。很大比例的肠闭锁患者会出现短肠综合征/肠衰竭(SGS/IF),这是一种肠道缺乏足够的长度和表面积来吸收足够的热量以满足营养需求的情况。目前,SGS/IF的治疗选择是有限的,适用于这些患者的一部分。本研究将探索胚胎肠的再生潜能。这一点很重要,因为目前还没有治疗方法能够使我们实现利用患者自身细胞替代SGS/IF患者肠道的长期目标。这项研究具有创新性,因为它开辟了两种范式转变的可能性。第一种可能性是我们实验室认识到胚胎肠在损伤后具有再生的潜力。第二种可能性是再生需要一个来自于
英文摘要
DESCRIPTION (provided by applicant): In this proposal we use a genetic mouse model of a congenital human defect to study a previously unknown regenerative mechanism within the embryonic intestine. The congenital defect is an intestinal atresia which forms prenatally and results in a segmental absence of a portion of the intestinal tube. Atresias present in the newborn period as an intestinal obstruction. A significant percentage of patients with intestinal atresia develop shortgut syndrome/Intestinal failure (SGS/IF), a condition where the intestine lacks sufficient length and surface area to absorb adequate calories in order to meet nutritional requirements. Currently, the therapeutic options for SGS/IF are limited and applicable to a subset of these patients. The proposed research will explore the regenerative potential of the embryonic intestine. This is significant because there are no therapies that enable us achieve our long-range goal of utilizing the patient's own cells to replace intestine in SGS/IF. This research is innovative because it has opened up the possibility of two paradigm shifts. The first possibility is the recognition by our laboratory that the embryonic intestine has the potential to regenerate after injury. The second possibility is that regeneration requires a cell derived from a
one germ layer (mesoderm) to transdifferentiate and function as a cell type normally derived from a separate germ layer (endoderm): a process also known as lineage reprogramming. Aim 1 will test the hypothesis that the endoderm compartment is invaded by a lateral plate mesoderm derived lineage of cells during the post-apoptotic phase of atresia formation. Aim 2 will test whether the invading cells are capable of fully transdifferentiating and assuming an endodermal fate following invasion. These hypotheses were formulated out of preliminary data from my laboratory. The expected results will illuminate a novel regenerative mechanism that enables the intestine to reconstitute the endoderm compartment and rescue development after injury. Expected results will open up an entirely new line of investigation in a previously unknown area of intestinal development. Furthermore, they will be the next steps towards exploiting this response to realize our very long-term goal of developing regenerative therapies for patients with SGS/IF: a disease that afflicts over 20,000 patients (NIH- PA-06-230) in this country.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of intestinal regeneration in a model of intestinal atresia
-
批准号:8491599
-
项目类别:
-
资助金额:$7.53万
-
财政年份:2013
-
负责人:Peter F Nichol
-
依托单位:
Role of Fgfr2IIIb in epithelial mesenchymal signaling in intestinal development
-
批准号:7871855
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2010
-
负责人:Peter F Nichol
-
依托单位:
Role of Fgfr2IIIb in epithelial mesenchymal signaling in intestinal development
-
批准号:8249462
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2010
-
负责人:Peter F Nichol
-
依托单位:
Role of Fgfr2IIIb in epithelial mesenchymal signaling in intestinal development
-
批准号:8066444
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2010
-
负责人:Peter F Nichol
-
依托单位:
Role of Fgfr2IIIb in epithelial mesenchymal signaling in intestinal development
-
批准号:8449184
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2010
-
负责人:Peter F Nichol
-
依托单位:
Role of Fgfr2IIIb in epithelial mesenchymal signaling in intestinal development
-
批准号:8637990
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2010
-
负责人:Peter F Nichol
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: